BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 2, 2013, Pages 160-165

  Chen, Kefei ^a   Huang, Wenqing ^b   Huang, Bin ^a   Wei, Yonggang ^a   Li, Bo ^a   Ge, Yan ^a   Qin, Yang ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

THY 1 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BROTHER OF THE REGULATOR OF IMPRINTED SITES GENE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CARDIOPULMONARY RESUSCITATION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

EID: 84872864267     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0242     Document Type: Article

References (28)

1. Cuffel C, Rivals J-P, Zaugg Y, et al. (2011) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 128:2625-2634.
2. D'Arcy V, Pore N, Docquier F, et al. (2008) BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98:571-579.
3. El-Osta A (2006) Mechanisms of abnormal gene expression in tumor cells. EXS No 96:351-361.
4. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma patho-genesis: from genes to environment. Nat Rev Cancer 6:674-687.
5. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33.
6. Filippova GN, Fagerlie S, Klenova EM, et al. (1996) An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16:2802-2813.
7. Filippova GN, Lindblom A, Meincke LJ, et al. (1998) A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 22:26-36.
8. Filippova GN, Qi CF, Ulmer JE, et al. (2002) Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter its DNA-binding specificity. Cancer Res 62: 48-52.
9. Ghochikyan A, Mkrtichyan M, Loukinov D, et al. (2007) Elici-tation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 178:566-573.
10. Gion M, Mione R, Leon AE, et al. (2001) A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37:355-363.
11. Hong JA, Kang Y, Abdullaev Z, et al. (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65:7763-7774.
12. Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics. CA Cancer J Clin 58:71-96.
13. Kensler TW, Qian GS, Chen JG, et al. (2003) Translational strategies for cancer prevention in liver. Nat Rev Cancer 3:321-329.
14. Kholmanskikh O, Loriot A, Brasseur F, et al. (2008) Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 122:777-784.
15. Klenova EM, Morse HC 3rd, Ohlsson R, et al. (2002) The novel BORIS+CTCF gene family is uniquely involved in the epige-netics of normal biology and cancer. Semin Cancer Biol 12:399-414.
16. Klenova EM, Nicolas RH, Paterson HF, et al. (1993) CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed inmultiple forms. Mol Cell Biol 13:7612-7624.
17. Lobanenkov VV, Nicolas RH, Adler VV, et al. (1990) A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5¢-flanking sequence of the chicken c-myc gene. Oncogene 5:1743-1753.
18. Loukinov DI, Pugacheva E, Vatolin S, et al. (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imp-rintingmarks in the soma. Proc Natl Acad Sci U S A 99: 6806-6811.
19. Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. Natl Cancer Inst 97:1498-1506.
20. Makovski A, Yaffe E, Shpungin S, et al. (2012) Intronic promoter drives the BORIS-regulated expression of FerT in colon carcinoma cells. J Biol Chem 287:6100-6112.
21. Mishra L, Banker T, Murray J, et al. (2009) Liver stem cells and hepatocellular carcinoma. Hepatology 49:318-329.
22. Qi CF, Martensson A, Mattioli R, et al. (2003) CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells. Proc Natl Acad Sci U S A 100:633-638.
23. Rasko JE, Klenova EM, Leon J, et al. (2001) Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res 61:6002-6007.
24. Risinger JI, Chandramouli GVR, Maxwell GL, et al. (2007) Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13:1713-1719.
25. Vatolin S, Abdullaev Z, Pack SD, et al. (2005) Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65:7751-7762.
26. Woloszynska-Read A, Zhang W, Yu J, et al. (2011) Coordinated cancer germline antigen promoter and global DNA hypo-methylation in ovarian cancer: association with BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 17: 2170-2180.
27. Yang ZF, Ho DW, Ng MN, et al. (2008) Significance of CD90 + cancer stem cells in human liver cancer. Cancer Cell 13: 153-166.
28. Zhang F, Chen XP, Zhang W, et al. (2008) Combined hepato-cellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52:224-232.